BioSpace News Archive

Job Trends

U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the accelerated approval submission of donanemab for the treatment of early symptomatic Alzheimer’s disease due to the limited number of patients with at least 12 months of drug exposure data provided in the submission.

January 19, 2023
·
6 min read
Biotech Beach

$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

Mabwell, an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. about 9MW3011.

January 19, 2023
·
6 min read
MicrobioSeq’s Plasmid Identification Service Boosts Microbial Characterization Research

MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA.

January 19, 2023
·
2 min read
Creative Proteomics Revised Its Molecular-Interaction Subsite for a Better User Experience

Creative Proteomics is an integrated CRO dedicated to providing a full range of services to support the development of proteomics projects

January 19, 2023
·
2 min read
Drug Development

Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection

Pulmobiotics SL and the Centre for Genomic Regulation (CRG) today announced the publication of preclinical results demonstrating that treatment using Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant Pseudomonas aeruginosa infections in the lungs of mice, thereby improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with ventilator-associated pneumonia (VAP).

January 19, 2023
·
7 min read
VISTA As Emerging Checkpoint Protein In Cancer Immunotherapy

Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2023 Report Highlights:

January 19, 2023
·
4 min read
Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality

Avectas, a cell engineering technology leader, announces the launch of the Solupore platform at the Advanced Therapies Week, Miami Beach Convention Centre, January 17th - 20th, 2023, Booth # 331

January 19, 2023
·
2 min read
NEW THERAPY TO TREAT RARE GASTROINTESTINAL STROMAL TUMOUR APPROVED FOR NEW ZEALAND PATIENTS

Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that a new therapy to treat rare gastrointestinal stromal tumour (GIST) shown to improve survival has now been approved in New Zealand.

January 19, 2023
·
7 min read
Biotech Beach

Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress

Biora Therapeutics, Inc. presented detailed results from its PM-611 study titled “Potential effects of food on a novel Drug Delivery System to deliver therapeutic compound into the colon” during the Crohn’s & Colitis Congress in Denver, CO, being held January 19-21, 2023.

January 19, 2023
·
6 min read
Business

Ansys to Release Fourth Quarter and FY 2022 Earnings on February 22, 2023

ANSYS, Inc. (NASDAQ: ANSS) announced today that the Company expects to release its fourth quarter and FY 2022 earnings on Wednesday, February 22, 2023, after the market closes.

January 19, 2023
·
2 min read